WHO monographs on selected medicinal plants - travolekar.ru

<strong>WHO</strong> <strong>monographs</strong> on selected medicinal plants
statistically significant. Thus, the study concluded that an extract of the
crude drug was as effective as mesalazine for the treatment of Crohn’s
disease.
The effect of an extract of the crude drug was assessed in patients with
ulcerative colitis, grade II or III (19). Patients were treated with the gum
resin preparation (350 mg three times daily for 6 weeks), and the effects
on stool properties, histolopathology and scan microscopy of rectal biopsies,
blood parameters including haemogloblin, serum iron, calcium,
phosphorus, proteins, total leukocytes and eosinophils were measured.
Patients receiving sulfasalazine (1 g three times daily) served as controls.
At the end of the treatment period, all parameters tested had improved
after treatment with Boswellia serrata gum resin and the results were similar
to those in the control group: 82% of treated patients went into remission
following treatment with the gum resin as did 75% of those treated
with sulfasalazine (19).
A controlled clinical trial assessed the efficacy of the crude drug in
patients with chronic colitis characterized by vague lower abdominal
pain, bleeding per rectum with diarrhoea and palpable tender descending
and sigmoid colon. Thirty patients with chronic colitis, 17 men and
13 women aged between 18 and 48 years, were included in the study.
Twenty of the patients were given a preparation of the gum resin of Boswellia
serrata (300 mg three times daily for 6 weeks) and 10 were given
sulfasalazine (1 g three times daily for 6 weeks) and served as controls.
Of 20 patients treated with Boswellia gum resin, 18 showed an improvement
in one or more of the parameters: stool properties; histopathology;
scanning electron microscopy; and measures of haemoglobin, serum
iron, calcium, phosphorus, proteins, total leukocytes and eosinophils.
Of 20 patients treated with Boswellia gum resin, 14 went into remission
whereas in the patients treated with sulfasalazine, the remission rate was
4 out of 10 (20).
Adverse reactions
Minor gastrointestinal side-effects have been reported in the clinical trials
(19–22).
Contraindications
Hypersensitivity or allergy to the crude drug.
Warnings
No information was found.
56